Multidisciplinary Radiopharmaceutical Therapy Symposium, February 17-18, 2026

Viewing 1-13 of 13 articles

ASTRO Radiopharmaceutical Symposium 2026: Toward Consensus in Lu-177 RPT Dosimetry: Comparing Multi-Timepoint and Single-Timepoint Imaging in Clinical Implementation

ASTRO Radiopharmaceutical Symposium 2026: Navigating Hematologic and Renal Dysfunction in RPT for Prostate Cancer

ASTRO Radiopharmaceutical Symposium 2026: Industry Perspective and Regulatory Challenges for RPT Clinical Trials

ASTRO Radiopharmaceutical Symposium 2026: RPT Clinical Trials — An Investigator and Drug Development Perspective

ASTRO Radiopharmaceutical Symposium 2026: Safety and Efficacy of 177Lu-PSMA-617 versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials  

ASTRO Radiopharmaceutical Symposium 2026: Clinical Outcomes among Patients Treated with 177Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer  

ASTRO Radiopharmaceutical Symposium 2026: Addressing Unmet Needs in Radiopharmaceutical Therapy  

ASTRO Radiopharmaceutical Symposium 2026: Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease  

ASTRO Radiopharmaceutical Symposium 2026: Factors Influencing Lesion Level Response after 177Lu-PSMA-Radioligand Therapy on Post Therapy SPECT/CT with Artificial Intelligence Annotation  

ASTRO Radiopharmaceutical Symposium 2026: Why Now is the Time to Build a Radiopharmaceutical Therapy Practice

ASTRO Radiopharmaceutical Symposium 2026: Personalized Multi-Timepoint Voxel Level Dosimetry in Patients with mCRPC Treated with 177Lu-PSMA-617 Therapy  

ASTRO Radiopharmaceutical Symposium 2026: Quantitative Radium-223 SPECT/CT for Tumor Dosimetry in Combined SBRT and RPT: Retrospective Analysis from a Phase II Trial  

ASTRO Radiopharmaceutical Symposium 2026: Increasing Access to Radiopharmaceutical Therapy: From Availability to Quality Access 